Skip to Content
Merck
CN
All Photos(1)

Documents

Y0001387

Candesartan cilexetil for peak identification

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Candesartan cilexetil, 2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116
Empirical Formula (Hill Notation):
C33H34N6O6
CAS Number:
145040-37-5
Molecular Weight:
610.66
MDL number:
MFCD00871371
UNSPSC Code:
41116107
PubChem Substance ID:
329831395
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

candesartan

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

InChI key

GHOSNRCGJFBJIB-UHFFFAOYSA-N

Gene Information

human ... AGTR1(185)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Candesartan cilexetil for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001388

Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard

Y0001389

Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard

1087803

Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard

1087814

Candesartan cilexetil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1087825

Candesartan cilexetil Related Compound B, United States Pharmacopeia (USP) Reference Standard

1087847

Candesartan cilexetil Related Compound D, United States Pharmacopeia (USP) Reference Standard

1087869

Candesartan cilexetil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1087870

Candesartan cilexetil Related Compound G, United States Pharmacopeia (USP) Reference Standard

PHR1854

Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2035

Candesartan cilexetil impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2021

Candesartan Cilexetil Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2036

Candesartan Cilexetil Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2020

Candesartan Cilexetil Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2018

Candesartan Cilexetil Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2022

Candesartan Cilexetil Impurity I, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2019

Candesartan Cilexetil Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2017

Candesartan Cilexetil Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1248

Candesartan cilexetil, British Pharmacopoeia (BP) Reference Standard

BP1249

Candesartan Cilexetil Impurity Standard, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H360D,H373

Hazard Classifications

Repr. 1B - STOT RE 2 Oral

Target Organs

Kidney,Blood

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ezequiel Balmori Melian et al.
Drugs, 62(5), 787-816 (2002-04-04)
The combination of candesartan cilexetil [an angiotensin II type 1 (AT(1)) receptor antagonist] plus hydrochlorothiazide (a thiazide diuretic), has been used in the treatment of patients with hypertension. The blood pressure (BP) lowering effect of various doses of this combination
Stephanie E Easthope et al.
Drugs, 62(8), 1253-1287 (2002-05-16)
Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator
J M Mallion et al.
Journal of human hypertension, 14 Suppl 2, S33-S41 (2000-11-22)
Candesartan is one of the first angiotensin II receptor antagonists (AIIRAs) to be developed. It binds tightly to and dissociates slowly from the angiotensin subtype 1 (AT1) receptor in vitro. These binding characteristics differ from those of losartan, which demonstrates
T Naka et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 120(12), 1261-1275 (2001-02-24)
Blockade of the action of angiotensin II (AII) has long been a target for the development of novel antihypertensive agents. We recently discovered a novel class of potent nonpeptide AII receptor antagonists, benzimidazole-7-carboxylic acids including candesartan. Candesartan is a highly
Caroline Fenton et al.
Drugs, 65(4), 537-558 (2005-03-01)
Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of hypertension and has
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service